Total submissions: 26
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000129680 | SCV000184479 | benign | Hereditary cancer-predisposing syndrome | 2014-07-14 | criteria provided, single submitter | clinical testing | Co-occurence with a mutation in another gene that clearly explains a proband's phenotype;Does not segregate with disease in family study (genes with incomplete penetrance);Other strong data supporting benign classification |
Genetic Services Laboratory, |
RCV000121638 | SCV000248163 | benign | not specified | 2016-10-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000199175 | SCV000252687 | benign | Neurofibromatosis, type 1 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000121638 | SCV000269458 | benign | not specified | 2015-06-22 | criteria provided, single submitter | clinical testing | p.Asp176Glu in exon 5 of NF1: This variant is not expected to have clinical sign ificance because it has been identified in 1% (67/6564) of Finnish chromosomes a nd 0.5% (307/66442) of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs112306990). |
Prevention |
RCV000121638 | SCV000306277 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000268253 | SCV000401689 | likely benign | Neurofibromatosis, familial spinal | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000323382 | SCV000401690 | likely benign | Café-au-lait macules with pulmonary stenosis | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000199175 | SCV000401691 | likely benign | Neurofibromatosis, type 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Illumina Laboratory Services, |
RCV000264802 | SCV000401692 | likely benign | Neurofibromatosis-Noonan syndrome | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. |
Center for Pediatric Genomic Medicine, |
RCV000034585 | SCV000510669 | benign | not provided | 2017-01-03 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000034585 | SCV000521056 | benign | not provided | 2016-05-24 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Center for Human Genetics, |
RCV000199175 | SCV000781873 | uncertain significance | Neurofibromatosis, type 1 | 2016-11-01 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000034585 | SCV000885828 | benign | not provided | 2020-07-23 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000121638 | SCV000917883 | benign | not specified | 2017-11-27 | criteria provided, single submitter | clinical testing | Variant summary: The NF1 c.528T>A (p.Asp176Glu) variant involves the alteration of a non-conserved nucleotide and is predicted to be damaging by 3/5 in silico tools. This variant was found in 1021/277004 control chromosomes (gnomAD), predominantly observed in the European (Finnish) subpopulation at a frequency of 0.011683 (301/25764). This frequency is about 56 times the estimated maximal expected allele frequency of a pathogenic NF1 variant (0.0002084), suggesting this is likely a benign polymorphism found primarily in the populations of European (Finnish) origin. This variant has been reported in several patients with neurofibromatosis type 1, including evidence of lack of cosegregation with disease and co-occurrence with other pathogenic variants in the same gene (Fahsold_2000, Ars_2003, and Nemethova_2013), strongly supporting for the benign outcome. In addition, multiple clinical diagnostic laboratories/reputable databases have classified this variant as benign. Taken together, this variant is classified as Benign. |
Mendelics | RCV000199175 | SCV001140338 | likely benign | Neurofibromatosis, type 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000199175 | SCV001478991 | benign | Neurofibromatosis, type 1 | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000121638 | SCV001879399 | benign | not specified | 2020-09-16 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000034585 | SCV002011204 | likely benign | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000034585 | SCV002498262 | benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | NF1: BS1, BS2 |
Sema4, |
RCV000129680 | SCV002527613 | benign | Hereditary cancer-predisposing syndrome | 2020-07-15 | criteria provided, single submitter | curation | |
Biesecker Lab/Clinical Genomics Section, |
RCV000034585 | SCV000043383 | no known pathogenicity | not provided | 2012-07-13 | no assertion criteria provided | research | Converted during submission to Benign. |
ITMI | RCV000121638 | SCV000085836 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Diagnostic Laboratory, |
RCV000121638 | SCV001743315 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000121638 | SCV001808697 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000121638 | SCV001974058 | benign | not specified | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV000034585 | SCV002036569 | likely benign | not provided | no assertion criteria provided | clinical testing |